公开(公告)号：US20090197851A1

公开(公告)日：2009-08-06

申请号：US12187169

申请日：2008-08-06

申请人： Stefan Anker ,  Andrew Coats ,  Hans-Dieter Volk ,  Mathias Rauchhaus ,  Ralf Reiner Schumann

发明人： Stefan Anker ,  Andrew Coats ,  Hans-Dieter Volk ,  Mathias Rauchhaus ,  Ralf Reiner Schumann

IPC分类号： A61K31/575 ,  A61P9/00

CPC分类号： A61K31/575

摘要： A method of treating, preventing or ameliorating chronic heart failure or acute heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation. A method of treating, preventing or ameliorating endotoxin-mediated immune activation in acute or chronic heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation.

摘要翻译： 一种治疗，预防或改善患者的慢性心力衰竭或急性心力衰竭的方法，该方法包括向患者施用有效量的：能够结合内毒素（脂多糖; LPS）分子的化合物，例如LPS 结合蛋白质，BPI，脂蛋白，胆汁酸或能够结合LPS的抗体，能够结合肠中的内毒素（脂多糖; LPS）分子或细菌的化合物，例如活性炭，胆汁酸或富勒氏土， 在肠道中基本上具有活性的抗菌剂，能够抑制细胞对内毒素（脂多糖; LPS）的反应的试剂，可能形成屏障或另外阻碍细菌或内毒素（LPS）易位的药剂， 从肠道到患者的流通。 一种在患者急性或慢性心力衰竭中治疗，预防或改善内毒素介导的免疫激活的方法，该方法包括向患者施用有效量的：能够结合内毒素（脂多糖; LPS）分子的化合物 ，例如LPS结合蛋白，BPI，脂蛋白，胆汁酸或能够结合LPS的抗体，能够结合肠中的内毒素（脂多糖; LPS）分子或细菌的化合物，例如活性炭，胆汁酸 或富勒的地球，在肠中基本上具有活性的抗菌剂，能够抑制细胞对内毒素（脂多糖; LPS）的反应的试剂，可能形成屏障或以其它方式阻碍细菌易位的药剂或 内毒素（LPS）从肠道进入患者的循环。